FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease
Joint Authors
Wu, Mei-Shin
Wong, Henry Sung-Ching
Tsai, Li-Jen
Lin, Ruo-Kai
Hsieh, Kai-Sheng
Hsu, Yu-Wen
Kuo, Ho-Chang
Klahan, Sukhontip
Chang, Wei Chiao
Woon, Peng Yeong
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-05-18
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Kawasaki disease (KD) is characterized by pediatric systemic vasculitis of an unknown cause.
The low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A) gene was reported to be involved in the susceptibility of KD.
DNA methylation is one of the epigenetic mechanisms that control gene expression; thus, we hypothesized that methylation status of CpG islands in FCGR2A promoter associates with the susceptibility and therapeutic outcomes of Kawasaki disease.
In this study, 36 KD patients and 24 healthy subjects from out-patient clinic were recruited.
Eleven potential methylation sites within the targeted promoter region of FCGR2A were selected for investigation.
We marked the eleven methylation sites from A to K.
Our results indicated that methylation at the CpG sites G, H, and J associated with the risk of KD.
CpG sites B, C, E, F, H, J, and K were found to associate with the outcomes of IVIG treatment.
In addition, CpG sites G, J, and K were predicted as transcription factors binding sites for NF-kB, Myc-Max, and SP2, respectively.
Our study reported a significant association among the promoter methylation of FCGR2A, susceptibility of KD, and the therapeutic outcomes of IVIG treatment.
The methylation levels of CpG sites of FCGR2A gene promoter should be an important marker for optimizing IVIG therapy.
American Psychological Association (APA)
Kuo, Ho-Chang& Hsu, Yu-Wen& Wu, Mei-Shin& Woon, Peng Yeong& Wong, Henry Sung-Ching& Tsai, Li-Jen…[et al.]. 2015. FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease. Mediators of Inflammation،Vol. 2015, no. 2015, pp.1-5.
https://search.emarefa.net/detail/BIM-1072426
Modern Language Association (MLA)
Kuo, Ho-Chang…[et al.]. FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease. Mediators of Inflammation No. 2015 (2015), pp.1-5.
https://search.emarefa.net/detail/BIM-1072426
American Medical Association (AMA)
Kuo, Ho-Chang& Hsu, Yu-Wen& Wu, Mei-Shin& Woon, Peng Yeong& Wong, Henry Sung-Ching& Tsai, Li-Jen…[et al.]. FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease. Mediators of Inflammation. 2015. Vol. 2015, no. 2015, pp.1-5.
https://search.emarefa.net/detail/BIM-1072426
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1072426